AstraZeneca_NNP Annual_JJ Report_NNP and_CC Form_NN 20-F_JJ 2002_CD Financial_NNP Statements_NNP www_NN ._.
com_NN 112_CD Principal_NN Subsidiaries_NNS ,_, Joint_NNP Ventures_NNP and_CC Associates_NNP Percentage_NN of_IN voting_VBG At_IN 31_CD December_NNP 2002_CD Country_NN share_NN capital_NN held_VBD Principal_NN activity_NN UK_NNP AstraZeneca_NNP UK_NNP Limited_NNP England_NNP 100_CD #_# Research_NNP ,_, production_NN ,_, marketing_NN AstraZeneca_NNP Insurance_NNP Company_NNP Limited_NNP England_NNP 100_CD Insurance_NNP and_CC reinsurance_NN underwriting_NN AstraZeneca_NNP Treasury_NNP Limited_NNP England_NNP 100_CD Treasury_NNP Continental_NNP Europe_NNP NV_NNP AstraZeneca_NNP SA_NNP Belgium_NNP 100_CD Marketing_NNP ASP_NNP SA_NNP France_NNP 100_CD Production_NN AstraZeneca_NNP Pharma_NNP SA_NNP France_NNP 100_CD Research_NNP ,_, production_NN ,_, marketing_NN AstraZeneca_NNP GmbH_NNP Germany_NNP 100_CD Development_NNP ,_, production_NN ,_, marketing_NN AstraZeneca_NNP Holding_NNP GmbH_NNP Germany_NNP 100_CD Production_NN ,_, marketing_NN AstraZeneca_NNP SpA_NNP Italy_NNP 100_CD Production_NN ,_, marketing_NN AstraZeneca_NNP Farmaceutica_NNP Spain_NNP SA_NNP Spain_NNP 100_CD Production_NN ,_, marketing_NN AstraZeneca_NNP AB_NNP Sweden_NNP 100_CD Research_NNP and_CC development_NN ,_, production_NN ,_, marketing_NN Astra_NNP Tech_NNP AB_NNP Sweden_NNP 100_CD Research_NNP and_CC development_NN ,_, production_NN ,_, marketing_NN AstraZeneca_NNP BV_NNP The_NNP Netherlands_NNP 100_CD Marketing_NNP The_DT Americas_NNPS AstraZeneca_NNP do_VBP Brasil_NNP Ltda_NNP ._.
Brazil_NNP 100_CD Production_NN ,_, marketing_NN AstraZeneca_NNP Canada_NNP Inc._NNP ._.
Canada_NNP 100_CD Research_NNP ,_, production_NN ,_, marketing_NN IPR_NNP Pharmaceuticals_NNP Inc._NNP ._.
Puerto_NNP Rico_NNP 100_CD Development_NNP ,_, production_NN ,_, marketing_NN AstraZeneca_NNP LP_NNP US_NNP 99_CD Development_NNP ,_, production_NN ,_, marketing_NN AstraZeneca_NNP Pharmaceuticals_NNP LP_NNP US_NNP 100_CD Development_NNP ,_, production_NN ,_, marketing_NN Salick_NNP Health_NNP Care_NNP ,_, Inc._NNP ._.
US_NNP 100_CD Provision_NNP of_IN disease-specific_JJ healthcare_NN services_NNS Zeneca_NNP Holdings_NNPS Inc._NNP ._.
US_NNP 100_CD Production_NN ,_, marketing_NN Asia_NNP ,_, Africa_NNP &_CC Australasia_NNP AstraZeneca_NNP Pty_NNP Limited_NNP Australia_NNP 100_CD Research_NNP ,_, production_NN ,_, marketing_NN AstraZeneca_NNP Pharmaceutical_NNP Co._NNP ._.
Limited_JJ China_NNP 100_CD Production_NN ,_, marketing_NN AstraZeneca_NNP Hong_NNP Kong_NNP Limited_NNP Hong_NNP Kong_NNP 100_CD Production_NN AstraZeneca_NNP KK_NNP Japan_NNP 80_CD Production_NNP ,_, marketing_NN #_# shares_NNS held_VBD directly_RB The_DT companies_NNS and_CC other_JJ entities_NNS listed_VBN above_RB are_VBP those_DT whose_WP$ results_NNS or_CC financial_JJ position_NN principally_RB affected_VBD the_DT figures_NNS shown_VBN in_IN the_DT Groups_NNS annual_JJ financial_JJ statements_NNS ._.
A_DT full_JJ list_NN of_IN subsidiaries_NNS ,_, joint_JJ ventures_NNS and_CC associates_NNS will_MD be_VB annexed_VBN to_TO the_DT Companys_NNPS next_JJ annual_JJ return_NN filed_VBN with_IN the_DT Registrar_NNP of_IN Companies_NNS ._.
The_DT country_NN of_IN registration_NN or_CC incorporation_NN is_VBZ stated_VBN alongside_IN each_DT company_NN ._.
The_DT accounting_NN dates_NNS of_IN principal_JJ subsidiaries_NNS and_CC associates_NNS are_VBP 31_CD December_NNP ,_, except_IN for_IN Salick_NNP Health_NNP Care_NNP ,_, Inc._NNP which_WDT is_VBZ 30_CD November_NNP ._.
AstraZeneca_NNP operates_VBZ through_IN 235_CD subsidiary_NN companies_NNS worldwide_VBP ._.
Products_NNPS are_VBP manufactured_VBN in_IN some_DT 20_CD countries_NNS worldwide_JJ and_CC are_VBP sold_VBN in_IN over_IN 100_CD countries_NNS ._.
